Chinese Journal of Blood Purification-Current Issue Current Issue http://journal01.magtechjournal.com/jwk3_cjbp EN-US http://journal01.magtechjournal.com/jwk3_cjbp/EN/1671-4091/current.shtml http://journal01.magtechjournal.com/jwk3_cjbp 1671-4091 <![CDATA[The relationship between lean body mass and risk of mortality in maintenance hemodialysis patients]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.002 LBM and others parameters were collected. A validated creatinine-based formula, LBM(kg)=0.34×serum creatinine (mg/dl)+5.58×gender (1 for female and 0 for male)+0.30×body weight(kg)+0.67×body height (inch)-0.23×URR (urea reduction ratio)-5.75(linch=0.1254m), was used to estimate LBM. The relationship between LBM and risk of mortality was then assessed. Results This cohort enrolled 187 MHD patients. Higher LBM was related to younger age (H=3.273, P=0.049), male (χ2=4.174, P=0.041), higher body weight (F=6.438, P=0.027) and body mass index(BMI)(F=5.997,P=0.029), higher serum albumin (F=3.811, P=0.043), creatinine(F=4.778,P=0.031), phosphorus(F=3.766,P=0.044) and intact parathyroid hormone(iPTH) (F=3.498, P=0.047). We divided the patients into 5 groups based on the 20th percentile of LBM values (<36.3, 36.3~40.7,40.7~44.9,44.9~49. 4and>49.4 kg). Patients in the 40.7~44.9 kg group was used as the reference group. After adjustment by multiple factors, we found that higher LBM was associated with lower mortality. Compared to the reference group, the risk of mortality increased by 31% in the lowest LBM group (HR: 1.31, 95% CI 1.11-1.53, P=0.043), while the risk decreased by 15% in the highest LBM group (HR: 0.85, 95% CI 0.72-0.95, P=0.038). Conclusions In MHD patients, higher LBM was associated with lower risk of mortality. We therefore have the possibility to predict risk of mortality by LBM in MHD patients.]]> <![CDATA[Efficacy and safety of paricalcitol on secondary hyperparathyroidism in hemodialysis patients: a retrospective study]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.003 weeks of paricalcitol treatment, the average iPTH level decreased by 73.01% of the baseline value to 346.38±223.72 pg/ml (t=6.578, P<0.001). In all of the 11 patients, the endpoint iPTH level decreased by more than 50% of the baseline value. At the endpoint of the study, iPTH levels reduced to 150-300pg/ml in 7 of the 11 patients and reached the compliance rate in 63.64% patients; serum calcium (t=2.952, P=0.088), phosphorus (t=1.305, P=0.206) and ALP (t= 1.513, P=0.145) had no significant differences compared to the baseline values in the 11 patients; VAS score was significantly lower than baseline value (t=15.976, P<0.001). One patient developed hypercalcemia (serum calcium 2.64mmol/L). Conclusions This study confirmed that paricalcitol can effectively treat SHPT in hemodialysis patients. It can reduce serum iPTH level and the bone pain VAS score, without changes of serum calcium and phosphorus.]]> <![CDATA[Effects of intradialytic exercise on inflammation, oxidative stress and endothelial function in patients with maintenance hemodialysis]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.004 <![CDATA[Clinical characteristics at the initiation of hemodialysis of end stage renal disease patients]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.005 2=
4.917, P=0.027). Conclusions DN was the first primary cause for initiating hemodialysis in ESRD patients in the past 3 years. DN patients initiated hemodialysis earlier and often due to refractory heart failure. The use of central vein catheterization for blood access was higher during the initiation of hemodialysis. Therefore, clinical management of CKD patients at the outpatient department should be reinforced. In addition, arteriovenous fistula operation should be considered before initiating hemodialysis to decrease the temporary vascular catheterization.]]>
<![CDATA[Application of automated peritoneal dialysis in patients with urgent-started peritoneal dialysis]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.006 <![CDATA[A comparative study of peritoneal dialysis and hemodialysis for end- stage renal disease children]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.007 June 2018 were collected. Clinical parameters, ESRD complications, time to transplantation and outcome were compared between PD and HD groups. Results A total of 231 cases who received PD and 50 cases who received HD were enrolled in this study. The mean age was younger in PD group than in HD group (t=-4.998, P<0.001). There were no significant differences in parameters during dialysis period, including hemoglobin (t=0.560, P=0.576), serum calcium (t=0.000, P=1.000) and phosphate (t=0.448, P=0.657), PTH (t=-1.828, P=0.069) and left ventricular mass index (Z=-0.750, P=0.455). The time to transplantation (t=-0.733, P=0.467) and outcome (P=0.334) were similar between PD and HD groups. Conclusion Most cases (82%) received PD as the first dialysis modality. ESRD complications, time to transplantation and outcomes were similar for children initiated on PD or HD therapy.]]> <![CDATA[Differentiation of intestinal macrophages towards proinflammatory phenotype aggravated the microinflammatory</br> status in uremia rats]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.008 which was related to the microinflammatory status of the rats.]]> <![CDATA[Current situation of bioimpedance analysis for body hydration management in maintaining hemodialysis patients]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.009 <![CDATA[Early dysfunction of arteriovenous fistula after total parathyroidectomy and autotransplantation in uremic patients with secondary hyperparathyroidism]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.012 <![CDATA[Correlation analysis of dialysis knowledge and self-management in hemodialysis patients in Gansu province]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.015 <![CDATA[Study on the application of symptom management consultants for the management of symptoms in maintenance hemodialysis patients]]> http://journal01.magtechjournal.com/jwk3_cjbp/EN/10.3969/j.issn.1671-4091.2019.06.016 2=43.973, P<0.001; for symptom group of cardiopulmonary symptoms, χ2=26.252, P<0.001; for symptom group of digestive symptoms, χ2=57.754, P< 0.001; for symptom group of emotional symptoms, χ2=34.001, P<0.001; for symptom group of water electrolyte, χ2=43.726, P<0.001); the quality of life score was higher than that in the control group (after intervention for one month, t=4.435, P<0.001; for 3 months, t=15.809, P<0.001; for 6 months, t=30.225, P<0.001); and the satisfaction score was also higher than that in the control group (after intervention for one month, t=19.139, P<0.001; for 3 months, t=20.919, P< 0.001; for 6 months, t=5.882, P<0.001). Conclusion The symptom management consultants for symptom management in MHD patients can reduce the incidence of symptoms and improve their quality of life and satisfaction, suitable to be widely used in clinical practice.]]>